Extended Use of Breast Cancer Drug Suggested

The widely prescribed drug tamoxifen already plays a major role in reducing the risk of death from breast cancer. But a new study suggests that women should be taking the drug for twice as long as is now customary, a finding that could upend the standard that has been in place for about 15 years.

In the study, patients who continued taking tamoxifen for 10 years were less likely to have the cancer come back or to die from the disease than women who took the drug for only five years, the current standard of care.

“Certainly, the advice to stop in five years should not stand,” said Prof. Richard Peto, a medical statistician at Oxford University and senior author of the study, which was published in The Lancet on Wednesday and presented at the San Antonio Breast Cancer Symposium.

Breast cancer specialists not involved in the study said the results could have the biggest impact on premenopausal women, who account for a fifth to a quarter of new breast cancer cases. Postmenopausal women tend to take different drugs, but some experts said the results suggest that those drugs might be taken for a longer duration as well.

“We’ve been waiting for this result,” said Dr. Robert W. Carlson, a professor of medicine at Stanford University. “I think it is especially practice-changing in premenopausal women because the results do favor a 10-year regimen.”

Dr. Eric P. Winer, chief of women’s cancers at the Dana-Farber Cancer Institute in Boston, said that even women who completed their five years of tamoxifen months or years ago might consider starting on the drug again.

Tamoxifen blocks the effect of the hormone estrogen, which fuels tumor growth in estrogen receptor-positive cancers that account for about 65 percent of cases in premenopausal women. Some small studies in the 1990s suggested that there was no benefit to using tamoxifen longer than five years, so that has been the standard.

About 227,000 cases of breast cancer are diagnosed each year in the United States, and an estimated 30,000 of them are in premenopausal women with estrogen receptor-positive cancer and prime candidates for tamoxifen. But postmenopausal women also take tamoxifen if they cannot tolerate the alternative drugs, known as aromatase inhibitors.

The new study, known as Atlas, included nearly 7,000 women with ER-positive disease who had completed five years of tamoxifen. They came from about three dozen countries. Half were chosen at random to take the drug another five years, while the others were told to stop.

In the group assigned to take tamoxifen for 10 years, 21.4 percent had a recurrence of breast cancer in the ensuing 10 years, meaning the period 5 to 14 years after their diagnoses. The recurrence rate for those who took only five years of tamoxifen was 25.1 percent.

About 12.2 percent of those in the 10-year treatment group died from breast cancer, compared with 15 percent for those in the control group.

There was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen. The difference came in later years, suggesting that tamoxifen has a carry-over effect that lasts long after women stop taking it.

Whether these differences are big enough to cause women to take the drug for twice as long remains to be seen.

“The treatment effect is real, but it’s modest,” said Dr. Paul E. Goss, director of breast cancer research at the Massachusetts General Hospital.

Tamoxifen has side effects, including endometrial cancer, blood clots and hot flashes, which cause many women to stop taking the drug. In the Atlas trial, it appears that roughly 40 percent of the patients assigned to take tamoxifen for the additional five years stopped prematurely.

Some 3.1 percent of those taking the extra five years of tamoxifen got endometrial cancer versus 1.6 percent in the control group. However, only 0.6 percent of those in the longer treatment group died from endometrial cancer or pulmonary blood clots, compared with 0.4 percent in the control group.

“Over all, the benefits of extended tamoxifen seemed to outweigh the risks substantially,” Trevor J. Powles of the Cancer Center London, said in a commentary published by The Lancet.

Dr. Judy E. Garber, director of the Center for Cancer Genetics and Prevention at Dana-Farber, said many women have a love-hate relationship with hormone therapies.

“They don’t feel well on them, but it’s their safety net,” said Dr. Garber, who added that the news would be welcomed by many patients who would like to stay on the drug. “I have patients who agonize about this, people who are coming to the end of their tamoxifen.”

Emily Behrend, who is a few months from finishing her five years on tamoxifen, said she would definitely consider another five years. “If it can keep the cancer away, I’m all for it,” said Ms. Behrend, 39, a single mother in Tomball, Tex. She is taking the antidepressant Effexor to help control the night sweats and hot flashes caused by tamoxifen.

Cost is not considered a huge barrier to taking tamoxifen longer because the drug can be obtained for less than $200 a year.

The results, while answering one question, raise many new ones, including whether even more than 10 years of treatment would be better still.

Perhaps the most important question is what the results mean for postmenopausal women. Even many women who are premenopausal at the time of diagnosis will pass through menopause by the time they finish their first five years of tamoxifen, or will have been pushed into menopause by chemotherapy.

Postmenopausal patients tend to take aromatase inhibitors like anastrozole or letrozole, which are more effective than tamoxifen at preventing breast cancer recurrence, though they do not work for premenopausal women.

Mr. Peto said he thought the results of the Atlas study would “apply to endocrine therapy in general,” meaning that 10 years of an aromatase inhibitor would be better than five years. Other doctors were not so sure.

The Atlas study was paid for by various organizations including the United States Army, the British government and AstraZeneca, which makes the brand-name version of tamoxifen.

Read More..

HUD secretary defends efforts to stabilize FHA finances

WASHINGTON — A top Obama administration official said a key government agency that has helped stabilize the housing market might be able to stay afloat next year, but he couldn't guarantee it wouldn't need a taxpayer bailout.

He warned lawmakers, however, not to make the situation worse by messing too much with how it does business.

In a Senate hearing Thursday, Housing and Urban Development Secretary Shaun Donovan cautioned lawmakers worried about the increasingly precarious finances of the Federal Housing Administration that making hasty changes to its operations could endanger the strengthening housing turnaround.

The FHA insures more than $1 trillion worth of mortgages and has backed about 14% of new loans made this year. It played a crucial role in keeping the housing market afloat after the subprime mortgage bubble burst, and now it is paying the price for bad loans it backed from 2007 to 2009.

Quiz: How much do you know about mortgages?

But severely tightening the agency's standards for insuring mortgages, typically made to first-time, lower income home buyers, could damp the recovery and lead to more foreclosures that would further reduce the size of the fund the FHA uses to cover its losses.

"We are seeing a recovery, but it is still fragile," Donovan told the Senate Banking Committee. "We don't want to hurt the market, and in turn the FHA fund, by going too far and stopping that recovery."

Still, some senators were critical of the way FHA operates and the steps taken over the last four years by HUD, which oversees the agency, to stabilize its finances. They want to move more quickly to address possible changes at the agency.

"It is time for serious reform of the FHA before it needs a taxpayer bailout, if it isn't too late already," said Sen. Richard Shelby (R-Ala.).

The FHA insures mortgages with as little as 3.5% down and has backed loans for people who went through foreclosures as recently as three years earlier. In its annual actuarial report to Congress, the agency said that its reserves to cover losses dropped into negative territory for the fiscal year that ended Sept. 30.

Under law, the FHA's net worth must not drop below 2% of the outstanding balances of the loans it guarantees. But hit by foreclosures and lower house prices, the agency's so-called reserve ratio has been dropping since 2006 and ended the 2012 fiscal year at negative 1.44%.

The agency, which is funded by mortgage insurance premiums it charges to homeowners, had $30.3 billion in cash reserves as of Sept. 30 to cover $46.6 billion in projected losses in coming years.

The shortfall could force it to tap the U.S. Treasury, as it is legally allowed to do, for the first time in its 78-year history.

Democrats and Republicans said they were concerned about that possibility. But while Republicans pushed for quicker action by the administration to shore up the agency, Democrats echoed Donovan in warning against acting precipitously.

"There is a clear case to be made in my mind that, but for FHA in the midst of this housing crisis, we would have a far greater crisis on our hands," said Sen. Robert Menendez (D-N.J.). "And so reconciling the fiduciary responsibilities here to the taxpayers as well as to the [FHA] mission to the people of America is incredibly important."

Donovan said the FHA has been raising the insurance premiums it charges to homeowners and plans another increase, by an average of about $13 a month, for new loans it backs. The agency also plans to sell at least 40,000 delinquent loans a year and streamline short sales to reduce losses from foreclosures.

The changes "have significantly decreased" the chances of a bailout, Donovan said. But pressed by Sen. David Vitter (R-La.), Donovan would not predict the likelihood the FHA would need to draw taxpayer money.

A determination would not be made until the end of the 2013 fiscal year, Donovan said.

But given the continued problems at the FHA, some Republicans weren't satisfied with the slow pace of changes.

Sen. Bob Corker (R-Tenn.) said he did not understand why the FHA was backing loans for so-called rebound buyers, borrowers who recently went through foreclosure.

Donovan said the agency was considering revising its standards for such buyers. But he stressed that some were responsible borrowers who simply lost their jobs during the Great Recession.

"We believe if somebody can show they are back at work and are a responsible borrower again, that's somebody we should work with," he said.

Donovan said Congress could help the FHA by enacting some changes that the agency is unable to make on its own.

He noted that lawmakers last year reduced loan limits for seized housing finance giants Fannie Mae and Freddie Mac to $625,500 but kept the FHA limit at $729,750. The move increased the FHA's exposure to large, potentially bad loans. Lowering the FHA limit would help the agency's finances, Donovan said.

jim.puzzanghera@latimes.com

Read More..

Jazz legend Dave Brubeck dies at 91

Dave Brubeck's pioneering style in pieces such as "Take Five" caught listeners' ears with exotic, challenging rhythms.

In the strait-laced Eisenhower 1950s, Dave Brubeck seemed, on one hand, deeply conventional. He didn't drink, smoke or take drugs. He favored expressions like "baloney!" and "you bet" over ruder alternatives. He had a prodigious work ethic that had been ground into him by his cowboy father on the family's California cattle ranch.

But rebellion was in Brubeck's soul. Schooled in piano by his musically gifted mother, he became a jazz man — outwardly square but quintessentially cool — whose genius at marrying spontaneity and unorthodox rhythms with classical forms became an enduring legacy.

Brubeck, the pianist and composer who pushed the boundaries of jazz for six decades and became one of the genre's most popular artists, died Wednesday, a day before his 92nd birthday.

The jazz maestro, who had a history of heart trouble, became unresponsive on his way to a medical appointment, said his longtime manager and producer Russell Gloyd. Brubeck's son, who was in the car with him, rushed him to a hospital in Norwalk, Conn., where he was pronounced dead.

Jazz guitarist Kenny Burrell called Brubeck "a true musical giant. He helped to keep jazz at a truly high level and he was very consistent in both his performance and composition."

He was best known for his work with his classic Dave Brubeck Quartet, which included longtime musical partner Paul Desmond on alto saxophone, Eugene Wright on bass and Joe Morello on drums. Brubeck's innovative ideas generated an enthusiastic response from a new audience of young listeners — as well as the players most directly connected with his music.

"When Dave is playing his best, it's a profoundly moving thing to experience, emotionally and intellectually," Desmond said in 1952 in the jazz publication Down Beat. "It's completely free, live improvisation ... the vigor and force of simple jazz, the harmonic complexities of Bartok and Milhaud, the form [and much of the dignity] of Bach and, at times, the lyrical romanticism of Rachmaninoff."

In the late 1950s, the group began exploring unusual rhythmic meters. By the end of the decade, the album "Time Out" had reached No. 2 on the pop music album charts, and a single off the album — with "Take Five" on one side and "Blue Rondo a la Turk" on the other — became the first jazz recording to sell more than a million copies.

Written by Desmond, "Take Five" became a universally recognized jazz classic despite the offbeat 5/4 meter.

The group's popularity began to climb in the mid-1950s when a series of live college recordings — "Jazz Goes to College," "Jazz Goes to Junior College" and "Jazz Goes to Oberlin" — was released. Brubeck appeared on the cover of Time magazine in 1954, only the second such honor for a jazz artist. (Louis Armstrong was first.)

The New Yorker described the quartet as "the world's best-paid, most widely traveled, most highly publicized, and most popular small group now playing improvised syncopated music."

But Brubeck's fascination with groundbreaking elements not generally included in the jazz styles of the '50s also made his music a target of widespread disparagement from jazz critics, who often referred to a "heavy-handed, bombastic approach" to piano improvising. The words directly contradicted another critical view, which identified the music of Brubeck and Desmond as another example of the "effete, laid-back, West Coast cool jazz" style."

Most of the criticism failed to recognize the complex range of elements — from stride piano to a Bach canon — that could course through a single piece. Brubeck often cited the positive response his music received from legendary jazz figures including Duke Ellington, Miles Davis and Charles Mingus, among others.

David Warren Brubeck was born Dec. 6, 1920, in Concord, northeast of Oakland. His father, Howard "Pete" Brubeck, was a cattle rancher, his mother, Elizabeth Ivey Brubeck, a pianist and music teacher. When he was 11, the family moved to a 45,000-acre ranch near Ione, in the Sierra foothills.

His older brothers Howard and Henry became classical musicians, but Dave preferred ranching and improvising pop songs on the piano. As a teenager, he played at dances on weekends.

Brubeck started out studying veterinary medicine at what is now the University of the Pacific in Stockton but switched to music at the suggestion of his science advisor. He managed to earn a bachelor's degree without learning to properly read music.

He was drafted into the Army after graduation in 1942, marrying his college sweetheart, Iola Marie Whitlock, just before he was sent to France in 1944.

His wife, who frequently wrote lyrics for his projects, survives him along with his daughter Catherine, his sons Darius, Chris, Dan and Matthew, 10 grandchildren and four great-grandchildren. Another son, Michael, died several years ago.

Discharged from the military in 1946, Brubeck went to Mills College in Oakland, studying with French composer Darius Milhaud and forming the Brubeck Octet, a musically adventurous group with an imaginative and avant-garde repertoire. Brubeck's trio, which he led from 1949 to 1951, provided a different, more intimate forum for his far-reaching ideas. The group, which included bassist Ron Crotty and drummer/vibist Cal Tjader, played standards and Brubeck's originals.

In 1951, Brubeck added Desmond to his trio. It was the beginning of a journey into national visibility that established Brubeck and Desmond as significant jazz figures. The quartet, which remained together until 1967 and was briefly reunited in 1976, a year before Desmond died, became the most important vehicle for Brubeck's playing and innovative musical ideas.

Read More..

Michael Strahan makes his Broadway debut in 'Elf'

NEW YORK (AP) — Michael Strahan has tackled something few football stars have attempted — Broadway.

The gap-toothed co-host of "Live with Kelly and Michael" made three short appearances at Wednesday's matinee of "Elf" and said he has new respect for Broadway performers.

"I was surprised at how nervous you get and the adrenaline and that feedback from the audience — it really was an amazing thing," the former football player said after the show. "To see these performers who do it every day — eight or nine times a week — is really amazing. I take my hat off to them."

Fans can see a behind-the-scenes recap on Thursday's TV show.

The musical is adapted from the Will Ferrell film from 2003 about Buddy, a human raised in the North Pole who travels to New York in search of his parents.

Strahan thought making his Broadway debut would be fun and represented a new experience for a guy who holds the single season sack record. He found himself more nervous than he has been for high-stakes football games or live TV.

"It's a little nerve-wracking because so many people depend on you, you want to get your line across and you have to play to the crowd. It's a lot more intricate with everyone hitting their marks. You don't want to be the guy that messes everyone up," he said.

Strahan, 41, played both a police officer and a Salvation Army Santa in the first act and later came on as himself in a scene with the real Santa in the second act. As he waited in the wings of the Al Hirschfeld Theatre, he saw the toll the musical takes on its dancers.

"Some of these performers are breathing as if they just went into a football game and played a 12-play drive," he joked. "I was tired walking up and down from my dressing room."

Strahan rehearsed for an hour in the morning with stage managers and associate director Casey Hushion. At 1 p.m., some in the cast came in early to work with him, including Jordan Gelber, who plays Buddy, and Beth Leavel, who plays Buddy's stepmother.

The audience was quiet when Strahan first appeared as an officer with another cop after Buddy gets kicked out of Macy's. But the seven-time Pro-Bowler and Super Bowl winner flashed his trademark smile and they went wild. More applause greeted him after he played a Salvation Army Santa as he and Buddy wrestled over the kettle bells.

In the second act, he waited to ask Santa for a present. Santa asked him his name, the newly minted actor said "Michael Strahan" and he then asked for a red Schwinn bicycle with a bell shaped like Miss Piggy. The crowd cheered when Strahan identified himself and he got another wide round of applause at the curtain call, where the cast gave him flowers.

Strahan was named in September as Kelly Ripa's permanent co-host aboard the morning show "Live with Kelly and Michael." A former defensive star who spent 15 years in the NFL, he is also a host of "Fox NFL Sunday."

He follows in the footsteps of Joe Namath, a quarterback nicknamed "Broadway Joe" who made an appearance on Broadway in 1983 as a replacement in a revival of "The Caine Mutiny Court-Martial."

Strahan would not rule out a return to the stage. "I will take it off my bucket list, but if the opportunity came across again, I might just take it up and do it again," he said. "I had a great time."

___

Online:

http://www.elfmusical.com

http://dadt.com/live

Read More..

Extended Use of Breast Cancer Drug Suggested

The widely prescribed drug tamoxifen already plays a major role in reducing the risk of death from breast cancer. But a new study suggests that women should be taking the drug for twice as long as is now customary, a finding that could upend the standard that has been in place for about 15 years.

In the study, patients who continued taking tamoxifen for 10 years were less likely to have the cancer come back or to die from the disease than women who took the drug for only five years, the current standard of care.

“Certainly, the advice to stop in five years should not stand,” said Prof. Richard Peto, a medical statistician at Oxford University and senior author of the study, which was published in The Lancet on Wednesday and presented at the San Antonio Breast Cancer Symposium.

Breast cancer specialists not involved in the study said the results could have the biggest impact on premenopausal women, who account for a fifth to a quarter of new breast cancer cases. Postmenopausal women tend to take different drugs, but some experts said the results suggest that those drugs might be taken for a longer duration as well.

“We’ve been waiting for this result,” said Dr. Robert W. Carlson, a professor of medicine at Stanford University. “I think it is especially practice-changing in premenopausal women because the results do favor a 10-year regimen.”

Dr. Eric P. Winer, chief of women’s cancers at the Dana-Farber Cancer Institute in Boston, said that even women who completed their five years of tamoxifen months or years ago might consider starting on the drug again.

Tamoxifen blocks the effect of the hormone estrogen, which fuels tumor growth in estrogen receptor-positive cancers that account for about 65 percent of cases in premenopausal women. Some small studies in the 1990s suggested that there was no benefit to using tamoxifen longer than five years, so that has been the standard.

About 227,000 cases of breast cancer are diagnosed each year in the United States, and an estimated 30,000 of them are in premenopausal women with estrogen receptor-positive cancer and prime candidates for tamoxifen. But postmenopausal women also take tamoxifen if they cannot tolerate the alternative drugs, known as aromatase inhibitors.

The new study, known as Atlas, included nearly 7,000 women with ER-positive disease who had completed five years of tamoxifen. They came from about three dozen countries. Half were chosen at random to take the drug another five years, while the others were told to stop.

In the group assigned to take tamoxifen for 10 years, 21.4 percent had a recurrence of breast cancer in the ensuing 10 years, meaning the period 5 to 14 years after their diagnoses. The recurrence rate for those who took only five years of tamoxifen was 25.1 percent.

About 12.2 percent of those in the 10-year treatment group died from breast cancer, compared with 15 percent for those in the control group.

There was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen. The difference came in later years, suggesting that tamoxifen has a carry-over effect that lasts long after women stop taking it.

Whether these differences are big enough to cause women to take the drug for twice as long remains to be seen.

“The treatment effect is real, but it’s modest,” said Dr. Paul E. Goss, director of breast cancer research at the Massachusetts General Hospital.

Tamoxifen has side effects, including endometrial cancer, blood clots and hot flashes, which cause many women to stop taking the drug. In the Atlas trial, it appears that roughly 40 percent of the patients assigned to take tamoxifen for the additional five years stopped prematurely.

Some 3.1 percent of those taking the extra five years of tamoxifen got endometrial cancer versus 1.6 percent in the control group. However, only 0.6 percent of those in the longer treatment group died from endometrial cancer or pulmonary blood clots, compared with 0.4 percent in the control group.

“Over all, the benefits of extended tamoxifen seemed to outweigh the risks substantially,” Trevor J. Powles of the Cancer Center London, said in a commentary published by The Lancet.

Dr. Judy E. Garber, director of the Center for Cancer Genetics and Prevention at Dana-Farber, said many women have a love-hate relationship with hormone therapies.

“They don’t feel well on them, but it’s their safety net,” said Dr. Garber, who added that the news would be welcomed by many patients who would like to stay on the drug. “I have patients who agonize about this, people who are coming to the end of their tamoxifen.”

Emily Behrend, who is a few months from finishing her five years on tamoxifen, said she would definitely consider another five years. “If it can keep the cancer away, I’m all for it,” said Ms. Behrend, 39, a single mother in Tomball, Tex. She is taking the antidepressant Effexor to help control the night sweats and hot flashes caused by tamoxifen.

Cost is not considered a huge barrier to taking tamoxifen longer because the drug can be obtained for less than $200 a year.

The results, while answering one question, raise many new ones, including whether even more than 10 years of treatment would be better still.

Perhaps the most important question is what the results mean for postmenopausal women. Even many women who are premenopausal at the time of diagnosis will pass through menopause by the time they finish their first five years of tamoxifen, or will have been pushed into menopause by chemotherapy.

Postmenopausal patients tend to take aromatase inhibitors like anastrozole or letrozole, which are more effective than tamoxifen at preventing breast cancer recurrence, though they do not work for premenopausal women.

Mr. Peto said he thought the results of the Atlas study would “apply to endocrine therapy in general,” meaning that 10 years of an aromatase inhibitor would be better than five years. Other doctors were not so sure.

The Atlas study was paid for by various organizations including the United States Army, the British government and AstraZeneca, which makes the brand name version of tamoxifen.

Read More..

Northridge shooting probe yields more arrests, sources say

Los Angeles Police Department detectives have made additional arrests in connection with a quadruple homicide in Northridge, sources familiar with the investigation said.

The sources would not immediately identify the suspects nor would they detail what offenses they were arrested for. One of the arrests took place in Las Vegas overnight; it was not clear where the others occurred.

Sources familiar with the investigation said the killings appeared to stem from a dispute over personal property, although they would not say what kind of items were involved.

Los Angeles City Councilman Mitchell Englander said one of the suspects was believed to have lived in the illegal boardinghouse where the shootings occurred. Englander stressed that the information came from people briefed on the case but outside the LAPD.

A news conference is planned for later Tuesday, when the LAPD is expected to reveal more information about the case.

Officers responded to the home in the 17400 block of Devonshire Street about 4:25 a.m. Sunday after a 911 caller reported yelling and shots fired, police said. Authorities found four people -- two men and two women -- shot dead outside.

No weapon was recovered at the home, prompting police to rule out a murder-suicide. Three of the victims -- a man and two women -- were shot on the walkway on the left side of the home, a source familiar with the case told The Times on Monday. They were all wearing hooded sweat shirts and were about two feet apart from one another. All three had at least one bullet wound to the head.

One victim was crumpled on her knees, the source said, her face buried in the palms of her hands, "almost like she was praying." The other two victims on the walkway were face down.

The fourth victim -- a man -- was farther away and appeared as if he was trying to run to the backyard when he was shot. He had at least one gunshot wound, according to the source.

"It looked like a quick kill," said the source, who spoke on the condition of anonymity because the case is ongoing.

The names of the victims have not been released. Police said the women were in their mid-20s; one man was in his mid-30s and the other man in his late 40s.

Authorities said the home was an illegal boardinghouse, with up to 17 people living in conditions that Englander described as "deplorable." The home had so much debris and so many partitions that one room could be accessed only through a window, he said.

A trail of extension cords led investigators to the backyard, where several makeshift living quarters had been assembled.

The owner of the home, Yag Kapil, said he rented out rooms but denied he was running a boardinghouse. Kapil, 78, who lives at the home, said he is bedridden and was sleeping at the time of the shootings. He said he didn't hear anything and didn't know the victims.

The slayings stunned the quiet Northridge street, which residents said was the kind where neighbors knew one another and walked to the grocery store or synagogue nearby.

"It's usually sleepy-time America," said Richard Rutherford, 58, who was awakened by the gunfire. The violent-crime rate for Northridge falls in the middle of all Los Angeles neighborhoods, but homicide is rare in the community, according to LAPD data analyzed in The Times' Crime L.A. database. In the previous six months, Northridge had one homicide out of the 89 violent crimes reported.

Since 2007 and before Sunday's quadruple homicide, Northridge had 11 homicides, 10 of them south of Nordhoff Street. The location of Sunday's slayings is on the border with Granada Hills, which typically has a much lower violent-crime rate than Northridge.

Read More..

32% of Young People Use Social Media in the Bathroom

Read More..

Huston's "Infrared" wins Bad Sex fiction prize

LONDON (AP) — It's the prize no author wants to win.

Award-winning novelist Nancy Huston won Britain's Bad Sex in Fiction award Tuesday for her novel "Infrared," whose tale of a photographer who takes pictures of her lovers during sex proved too revealing for the judges.

The choice was announced by "Downton Abbey" actress Samantha Bond during a ceremony at the Naval & Military Club in London.

Judges of the tongue-in-cheek prize — which is run by the Literary Review magazine — said they were struck by a description of "flesh, that archaic kingdom that brings forth tears and terrors, nightmares, babies and bedazzlements," and by a long passage that builds to a climax of "undulating space."

Huston, who lives in Paris, was not on hand to collect her prize. In a statement read by her publicist, the 59-year-old author said she hoped her victory would "incite thousands of British women to take close-up photos of their lovers' bodies in all states of array and disarray."

The Canada-born Huston, who writes in both French and English, is the author of more than a dozen novels, including "Plainsong" and "Fault Lines." She has previously won France's Prix Goncourt prize and was a finalist for Britain's Orange Prize for fiction by women.

She is only the third woman to win the annual Bad Sex prize, founded in 1993 to name and shame authors of "crude, tasteless and ... redundant passages of sexual description in contemporary novels."

Some critics, however, have praised the sexual passages in "Infrared." Shirley Whiteside in the Independent on Sunday newspaper said there were "none of the lazy cliches of pornography or the purple prose of modern romantic fiction" — though she conceded the book's sex scenes were "more perfunctory than erotic."

Huston beat finalists including previous winner Tom Wolfe — for his passage in "Back to Blood" describing "his big generative jockey" — and Booker Prize-nominated Nicola Barker, whose novel "The Yips" compares a woman to "a plump Bakewell pudding."

Previous recipients of the dubious honor, usually accepted with good grace, include Sebastian Faulks, the late Norman Mailer and the late John Updike, who was awarded a Bad Sex lifetime achievement award in 2008.

___

Online: http://www.literaryreview.co.uk

Read More..

Stocks close lower as budget talks continue

Stocks are closed slightly lower on Wall Street as budget talks continue in Washington.

The Dow Jones industrial average fell 14 points to close at 12,952 Tuesday. It traded in a narrow range of just 82 points.

The Standard and Poor's 500 index lost two points to 1,407. The Nasdaq composite was down five and a half points at 2,997.

Investors are waiting on developments from Washington in the budget talks, which are aimed at avoiding a series of sharp government spending cuts and tax increases that begin to kick in Jan. 1.

Big Lots soared after the discount retailer raised its forecast for full-year profits.

Falling stocks narrowly outnumbered rising ones on the New York Stock Exchange. Volume was light at 3.2 billion shares.

Read More..

Two Mexican nationals charged in killing of U.S. Coast Guardsman

Federal prosecutors charged two Mexican nationals in connection with killing U.S. Coast Guardsmen Terrell Horne III after they allegedly rammed his vessel with a drug-smuggling panga boat.

The two men, boat captain Jose Mejia-Leyva and Manuel Beltra-Higuera, are expected to appear in court Monday afternoon to face charges that they killed a federal officer.

Horne, 34, of Redondo Beach, was killed Sunday after suspected smugglers in a panga rammed his vessel off the Ventura County coast. He died of severe head trauma, officials said.

The Redondo Beach resident was second in command of the Halibut, an 87-foot patrol cutter based in Marina del Rey. Authorities said they could not recall a Coast Guard chief petty officer being killed in such a manner off the coast of California.

Early Sunday morning, the Halibut was dispatched to investigate a boat operating near Santa Cruz Island, the largest of California's eight Channel Islands. The island is roughly 25 miles southwest of Oxnard.

The boat, first detected by a patrol plane, had come under suspicion because it was operating in the middle of the night without lights and was a "panga"-style vessel, an open-hulled boat that has become "the choice of smugglers operating off the coast of California," said Coast Guard spokesman Adam Eggers.

The Coast Guard cutter contains a smaller boat, a rigid-hull inflatable used routinely for search-and-rescue operations and missions that require a nimble approach. When Horne and his team approached in the inflatable, the suspect boat gunned its engine, maneuvered directly toward the Coast Guard inflatable, rammed it and fled.

The impact knocked Horne and another guardsman into the water. Both were quickly plucked from the sea. Horne had suffered a traumatic head injury. While receiving medical care, he was raced to shore aboard the Halibut. Paramedics met the Halibut at the pier in Port Hueneme and declared Horne dead at 2:21 a.m.

The second crew member knocked into the water suffered minor injuries and was treated and released from a hospital later Sunday. He was not identified.

Read More..